Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis

Hu, Qiong; Tang, Xing-zhou; Liu, Fang; Liu, Dewu; Cao, Bo

doi:10.1177/17562848231166227

Cited by 5 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, anti-IL17 drugs are highly effective in treating psoriatic arthritis [27], but they are contraindicated in IBD [28]. Conversely, anti-integrin therapies like vedolizumab are effective in treating IBD [29] but do not affect the joints or the skin.…”

Section: Discussionmentioning

confidence: 99%

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey

Vernero,

Bezzio,

Ribaldone

et al. 2024

JCM

View full text Add to dashboard Cite

(1) Background: Inflammatory bowel disease (IBD) is frequently associated to other immune-mediated inflammatory diseases (IMIDs). This study aims at assessing physicians’ awareness of the issue and the current status of IMID management. (2) Methods: A web-based survey was distributed to all 567 physicians affiliated to IG-IBD. (3) Results: A total of 249 (43.9%) physicians completed the survey. Over 90% of the responding physicians were gastroenterology specialists, primarily working in public hospitals. About 51.0% of the physicians had access to an integrated outpatient clinic, where gastroenterologists collaborated with rheumatologists and 28.5% with dermatologists. However, for 36.5% of physicians, integrated ambulatory care was not feasible. Designated appointment slots for rheumatologists and dermatologists were accessible to 72.2% and 58.2% of physicians, respectively, while 20.1% had no access to designated slots. About 5.2% of physicians report investigating signs or symptoms of IMIDs only during the initial patient assessment. However, 87.9% inquired about the presence of concomitant IMIDs at the initial assessment and actively investigated any signs or symptoms during subsequent clinical examination. (4) Conclusions: While Italian physicians recognize the importance of IMIDs associated with IBD, organizational challenges impede the attainment of optimal multidisciplinary collaboration. Efforts should be directed toward enhancing practical frameworks to improve the overall management of these complex conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey

Vernero,

Bezzio,

Ribaldone

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

“…In recent years, in the research progress of UC therapeutic drugs, traditional drugs such as 5-aminosalicylic acid, glucocorticoids and immunosuppressants have formed standardized treatment in the treatment plan [7][8][9]. Although there is a certain effect, the treatment effect is not ideal from the perspective of the tolerance of UC patients to the drug and the physiological health status after surgery [10].…”

Section: Introductionmentioning

confidence: 99%

Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway

Wu,

Jiang,

Yuan

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Background Ulcerative colitis (UC) is an inflammatory disease of the digestive tract. Rauwolfia polysaccharide (Rau) has therapeutic effects on colitis in mice, but its mechanism of action needs to be further clarified. In the study, we explored the effect of Rau on the UC cell model induced by Lipopolysaccharide (LPS). Methods We constructed a UC cell model by stimulating HT-29 cells with LPS. Dextran sodium sulfate (DSS) was used to induce mice to construct an animal model of UC. Subsequently, we performed Rau administration on the UC cell model. Then, the therapeutic effect of Rau on UC cell model and was validated through methods such as Cell Counting Kit-8 (CCK8), Muse, Quantitative real‑time polymerase chain reaction (RT-qPCR), Western blotting, and Enzyme-linked immunosorbent assay (ELISA). Results The results showed that Rau can promote the proliferation and inhibit the apoptosis of the HT-29 cells-induced by LPS. Moreover, we observed that Rau can inhibit the expression of NOS2/JAK2/STAT3 in LPS-induced HT-29 cells. To further explore the role of NOS2 in UC progression, we used siRNA technology to knock down NOS2 and search for its mechanism in UC. The results illustrated that NOS2 knockdown can promote proliferation and inhibit the apoptosis of LPS-induced HT-29 cells by JAK2/STAT3 pathway. In addition, in vitro and in vivo experiments, we observed that the activation of the JAK2/STAT3 pathway can inhibit the effect of Rau on DSS-induced UC model. Conclusion In short, Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway. This study provides a theoretical clue for the treatment of UC by Rau.

show abstract

Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies

Tursi,

Mocci,

Del Gaudio

et al. 2024

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

Vedolizumab subcutaneous formulation maintenance therapy for patients with IBD: a systematic review and meta-analysis

Cited by 5 publications

References 70 publications

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey

Immune-Mediated Inflammatory Diseases Awareness and Management among Physicians Treating Patients with Inflammatory Bowel Disease: An IG-IBD Survey

Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway

Clinical use of biologics for Crohn’s disease in adults: lessons learned from real-world studies

Contact Info

Product

Resources

About